Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Hematology Drugs Market: By Drug Class, By Route of Administration, Â By Drug Type, and Geography
1. Executive Summary |
2. Global Hematology Drugs Market Introduction |
2.1. Global Hematology Drugs Market – Taxonomy |
2.2. Global Hematology Drugs Market –Definitions |
2.2.1. By Drug Class |
2.2.2. By Route of Administration |
2.2.3. By Drug Type |
2.2.4. By Region |
3. Global Hematology Drugs Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Hematology Drugs Market Dynamic Factors - Impact Analysis |
3.6. Global Hematology Drugs Market – Competition Landscape |
4. Global Hematology Drugs Market Analysis,2017-2021 and Forecast, 2022-2028 |
4.1. Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Hematology Drugs Market, By Drug Class, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.1. Asparaginase-Specific Enzyme |
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anthracycline Antibiotic |
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Antimetabolites |
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Enediyne Antitumor Antibiotics |
5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Hypomethylating Agents |
5.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Antithrombotic Agents |
5.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Tyrosine Kinase Inhibitors |
5.7.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Hematology Drugs Market Forecast, By Route of Administration, 2017-2021 and Forecast, 2021 – 2027 (Revenue, US$ Mn) |
6.1. Oral |
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Hematology Drugs Market, By Drug Type, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
7.1. Small Molecules |
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Biologicals |
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Hematology Drugs Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.1. North America |
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Region, 2022-2028 |
9. North America Hematology Drugs Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Asparaginase-Specific Enzyme |
9.1.2. Anthracycline Antibiotic |
9.1.3. Antimetabolites |
9.1.4. Enediyne Antitumor Antibiotics |
9.1.5. Hypomethylating Agents |
9.1.6. Antithrombotic Agents |
9.1.7. Tyrosine Kinase Inhibitors |
9.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Oral |
9.2.2. Parenteral |
9.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Small Molecules |
9.3.2. Biologicals |
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028 |
9.6. North America Hematology Drugs Market Dynamics – Trends |
10. Europe Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
10.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Asparaginase-Specific Enzyme |
10.1.2. Anthracycline Antibiotic |
10.1.3. Antimetabolites |
10.1.4. Enediyne Antitumor Antibiotics |
10.1.5. Hypomethylating Agents |
10.1.6. Antithrombotic Agents |
10.1.7. Tyrosine Kinase Inhibitors |
10.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Oral |
10.2.2. Parenteral |
10.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Small Molecules |
10.3.2. Biologicals |
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Poland |
10.4.8. Rest of Europe |
10.5. Europe Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028 |
10.6. Europe Hematology Drugs Market Dynamics – Trends |
11. Asia-Pacific Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
11.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Asparaginase-Specific Enzyme |
11.1.2. Anthracycline Antibiotic |
11.1.3. Antimetabolites |
11.1.4. Enediyne Antitumor Antibiotics |
11.1.5. Hypomethylating Agents |
11.1.6. Antithrombotic Agents |
11.1.7. Tyrosine Kinase Inhibitors |
11.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Oral |
11.2.2. Parenteral |
11.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Small Molecules |
11.3.2. Biologicals |
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028 |
11.6. Asia-Pacific Hematology Drugs Market Dynamics – Trends |
12. Latin America Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
12.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Asparaginase-Specific Enzyme |
12.1.2. Anthracycline Antibiotic |
12.1.3. Antimetabolites |
12.1.4. Enediyne Antitumor Antibiotics |
12.1.5. Hypomethylating Agents |
12.1.6. Antithrombotic Agents |
12.1.7. Tyrosine Kinase Inhibitors |
12.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Oral |
12.2.2. Parenteral |
12.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Small Molecules |
12.3.2. Biologicals |
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028 |
12.6. Latin America Hematology Drugs Market Dynamics – Trends |
13. Middle East and Africa Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
13.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Asparaginase-Specific Enzyme |
13.1.2. Anthracycline Antibiotic |
13.1.3. Antimetabolites |
13.1.4. Enediyne Antitumor Antibiotics |
13.1.5. Hypomethylating Agents |
13.1.6. Antithrombotic Agents |
13.1.7. Tyrosine Kinase Inhibitors |
13.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Oral |
13.2.2. Parenteral |
13.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Small Molecules |
13.3.2. Biologicals |
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028 |
13.6. MEA Hematology Drugs Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Eli Lilly |
14.2.2. Novartis |
14.2.3. Celgene |
14.2.4. Amgen Inc. |
14.2.5. Sanofi S.A. |
14.2.6. Pfizer Inc. |
14.2.7. Jazz Pharmaceuticals |
14.2.8. Bristol-Myers Squibb Company |
14.2.9. Roche Holding AG |
14.2.10. Baxalta |
14.2.11. Angstrom Pharmaceuticals |
15. Research Methodology |
16. Key Assumptions and Acronyms |
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players